"Oligonucleotides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Polymers made up of a few (2-20) nucleotides. In molecular genetics, they refer to a short sequence synthesized to match a region where a mutation is known to occur, and then used as a probe (OLIGONUCLEOTIDE PROBES). (Dorland, 28th ed)
| Descriptor ID |
D009841
|
| MeSH Number(s) |
D13.695.578.424
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Oligonucleotides".
Below are MeSH descriptors whose meaning is more specific than "Oligonucleotides".
This graph shows the total number of publications written about "Oligonucleotides" by people in this website by year, and whether "Oligonucleotides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 2 | 3 |
| 1996 | 2 | 2 | 4 |
| 1997 | 0 | 3 | 3 |
| 1998 | 1 | 1 | 2 |
| 1999 | 1 | 3 | 4 |
| 2000 | 2 | 5 | 7 |
| 2001 | 3 | 6 | 9 |
| 2002 | 0 | 5 | 5 |
| 2003 | 2 | 8 | 10 |
| 2004 | 1 | 5 | 6 |
| 2005 | 2 | 9 | 11 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 3 | 4 |
| 2008 | 2 | 5 | 7 |
| 2009 | 1 | 5 | 6 |
| 2010 | 0 | 4 | 4 |
| 2011 | 4 | 5 | 9 |
| 2012 | 1 | 6 | 7 |
| 2013 | 4 | 6 | 10 |
| 2014 | 2 | 2 | 4 |
| 2015 | 2 | 4 | 6 |
| 2016 | 1 | 0 | 1 |
| 2018 | 6 | 1 | 7 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 2 | 4 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 2 | 3 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oligonucleotides" by people in Profiles.
-
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. N Engl J Med. 2024 May 16; 390(19):1781-1792.
-
A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis. Kidney Int. 2024 Jul; 106(1):145-153.
-
Concern about Tominersen in Patients with Huntington's Disease. Reply. N Engl J Med. 2024 Mar 14; 390(11):1059.
-
Tominersen in Adults with Manifest Huntington's Disease. N Engl J Med. 2023 Dec 07; 389(23):2203-2205.
-
Novel use of nusinersen as a therapeutic bridge to onasemnogene abeparvovec-xioi in a premature neonate with type 1 spinal muscular atrophy. Muscle Nerve. 2022 08; 66(2):E8-E10.
-
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. Future Oncol. 2022 Jul; 18(22):2393-2402.
-
Cost-Efficient Sequence-Based Nonextensible Oligonucleotide in Real-Time PCR and High-Throughput Sequencing. ACS Sens. 2022 04 22; 7(4):1165-1174.
-
Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2022 01; 22(1):52-59.
-
A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2021 05; 21(5):309-317.e3.
-
The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin. Nat Cell Biol. 2020 11; 22(11):1332-1345.